DelveInsight’s “Fucosidosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Fucosidosis, historical and forecasted epidemiology as well as the Fucosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Fucosidosis market report provides current treatment practices, emerging drugs, Fucosidosis market share of the individual therapies, and current and forecasted Fucosidosis market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Fucosidosis treatment practices/algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Fucosidosis is a rare genetic disorder characterized by a deficiency of the enzyme alpha-L-fucosidase, which is required to break down (metabolize) certain complex compounds (e.g., fucose-containing glycolipids or fucose-containing glycoproteins). Fucose is a type of sugar required by the body to perform certain functions (essential sugar). The inability to breakdown fucose-containing compounds results in their accumulation in various tissues in the body. Fucosidosis results in progressive neurological deterioration, skin abnormalities, growth retardation, skeletal disease, and coarsening of facial features. The symptoms and severity of fucosidosis are highly variable and the disorder represents a disease spectrum in which individuals with mild cases have been known to live into the third or fourth decades. Individuals with severe cases of fucosidosis can develop life-threatening complications early in childhood.
Fucosidosis Epidemiology Insights:
Seventy-seven patients affected with fucosidosis of which 19 had not been reported before have been identified. A major aim of the present study was to define the natural history of fucosidosis. The clinical picture of fucosidosis consists of progressive mental (95%) and motor (87%) deterioration, coarse facies (79%), growth retardation (78%), recurrent infections (78%), dysostosis multiplex (58%), angiokeratoma corporis diffusum (52%), visceromegaly (44%), and seizures (38%). Whereas the original fucosidosis patients described by Durand et al. (J. Pediatr 75:665-674, 1969) were decerebrate and died before age 5 years, most fucosidosis patients have a slower course of degeneration. Mortality before age 5 years was observed in only 7 patients (9%), whereas 36 patients (64%) reached the second-decade
Fucosidosis Epidemiology Segmentation
Total Fucosidosis prevalent cases
Total Fucosidosis incident cases
Total Fucosidosis diagnostic cases
Total Fucosidosis treatment cases
Fucosidosis Market Outlook
The Fucosidosis market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Fucosidosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. This segment gives a thorough detail of the Fucosidosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Learn more by requesting for sample @ Fucosidosis Market Trends
Table of Contents
Executive Summary of Fucosidosis
Disease Background and Overview
Epidemiology and patient population
Fucosidosis Emerging Therapies
Fucosidosis Market Outlook
Market Access and Reimbursement of Therapies
Fucosidosis Report Methodology
Click here to read more about Fucosidosis Market Trends
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States